Redasemtide Phase 2 Readouts Show Ulcer Closure in Small Study, Missed Stroke Endpoint

Shionogi reports ulcer closure in three of four participants in one study, but its larger stroke study did not meet the primary efficacy endpoint.

For research use only. Not for human consumption.